Plant-derived mAbs have effective anti-cancer activities by increasing ganglioside expression in colon cancers.

Research paper by Jae-Sung JS Ryu, Ju-Taek JT Lee, Malg-Um MU Lim, Mi-Ran MR Hwang, Kyung-A KA Hwang, Young-Ho YH Cho, Jeong-Hwan JH Lee, Kisung K Ko, Young-Kug YK Choo

Indexed on: 01 Oct '13Published on: 01 Oct '13Published in: Biotechnology Letters


An epithelial cell adhesion molecule (EpCAM) was selectively expressed in human colorectal carcinoma. Treatment with plant-derived anti-EpCAM mAb (mAbP CO17-1A) and RAW264.7 cells inhibited cell growth in the human colorectal cancer cell line SW620. In SW620 treated with mAbP CO17-1A and RAW264.7 cells, expression of p53 and p21 increased, whereas the expression of G1 phase-related proteins, cyclin D1, CDK4, cyclin E, and CDK2, decreased, similar to mammalian-derived mAb (mAbM) CO17-1A. Similar to mAbM CO17-1A, treatment with mAbP CO17-1A and RAW264.7 cell decreased the expression of anti-apoptotic protein, Bcl-2, but the expression of pro-apoptotic proteins Bax, TNF-α, caspase-3, caspase-6, caspase-8 and caspase-9, increased. Cells treated with mAbP CO17-1A and RAW264.7 cells expressed metastasis-related gangliosides, GM1 and GD1a, similar to mAbM CO17-1A. These results suggest that mAbP CO17-1A is as effective on anti-cancer activity as mAbM CO17-1A.